When “Mentions” Become Misleading: Why Scientific Rigor Matters in Kratom Research

In March 2026, a study published in JAMA Network Open examined trends in kratom-related clinical encounters using electronic health records from a major U.S. hospital system. The authors reported an increase in hospitalizations where kratom was “mentioned” in clinical notes from 2017 to 2024, framing this as a signal of growing clinical concern.

At first glance, this type of dataset appears compelling. But as I highlighted in my peer-reviewed comment published alongside the article, the interpretation of these findings raises serious concerns about research integrity, methodological rigor, and the downstream consequences for public health policy.

This is not just about kratom. It is about how evidence is generated, interpreted, and ultimately used to shape law, medicine, and patient access.

The Problem: “Mentions” Are Not Outcomes

The study relies on a fundamental proxy: the presence of the word “kratom” in clinician notes. This is not the same as causation, diagnosis, or even confirmed use. As the authors themselves acknowledge, documentation of kratom “does not imply causality or attribution” for the clinical encounter.

Yet, in practice, this distinction often disappears once findings are translated into headlines, policy briefs, or regulatory narratives.

This is a classic example of what happens when weak proxies are treated as meaningful clinical signals. A mention could reflect:

• incidental disclosure by a patient

• historical or remote use

• concurrent polysubstance exposure

• clinician bias or documentation variability

Without dose, product type, timing, or toxicological confirmation, these data cannot support conclusions about harm, risk trends, or causality.

Why This Matters for Drug Policy

In drug policy, evidence does not exist in a vacuum. Studies like this are frequently cited in legislative hearings, regulatory actions, and media coverage. When methodological limitations are not clearly communicated or are overlooked, they can contribute to:

• exaggerated perceptions of risk

• misclassification of substances

• policy decisions that outpace the science

We have seen this pattern repeatedly across substance categories, from cannabis to psychedelics to emerging alkaloid products. Kratom and its constituent compounds are now following the same trajectory.

The risk is not simply academic. Poorly interpreted data can lead to scheduling decisions, product bans, or clinical guidance that restricts access for patients while failing to address actual drivers of harm.

Research Integrity Is Not Optional

My work in research integrity focuses on a simple principle: conclusions must match the quality and limits of the data.

In this case, the gap between what the data show and how they may be interpreted is significant.

High-quality evidence in this space requires:

• clear differentiation between exposure and causation

• standardized toxicological confirmation (not keyword searches)

• detailed reporting of product type, dose, and context

• appropriate control for polysubstance use

Without these elements, studies risk contributing more noise than signal.

This is not a critique of studying kratom. It is a call to study it correctly.

The Broader Issue: Evidence-Based Medicine vs. Narrative Drift

Evidence-based medicine is not just about publishing data. It is about ensuring that data are interpreted within their proper context and limitations.

When observational signals are overinterpreted, especially in politically sensitive areas like drug policy, we see what I call “narrative drift” - where preliminary or weak evidence becomes amplified into perceived consensus.

That process erodes trust in science, undermines clinical decision-making, and ultimately harms patients.

A Path Forward

Kratom research is still in its early stages, and that is precisely why methodological rigor matters.

Instead of relying on indirect proxies, future research should prioritize:

• prospective clinical studies

• pharmacokinetic and pharmacodynamic characterization

• standardized adverse event reporting

• differentiation between traditional plant products and high-concentration formulations

Most importantly, policymakers and clinicians must be trained to critically evaluate the strength of evidence, not just the direction of a trend.

Conclusion

Ultimately, the implications extend well beyond a single study. At issue is not the study itself, but how its findings may be interpreted and used.

This distinction is particularly important in the current policy environment, where kratom and 7-hydroxymitragynine (7-OH) products are being rapidly restricted or proposed for scheduling across multiple states in 2025 and 2026, despite widespread use by an estimated more than 20 million Americans.

When methodological limitations are not carried forward into these policy discussions, the result is evidence that appears stronger than it is - and decisions that may outpace the underlying science.

Science must lead policy - not the other way around.

When weak signals are presented as strong evidence, the consequences extend far beyond a single paper. They shape narratives, influence regulation, and ultimately determine what options patients have access to.

If we care about public health, we must hold the line on scientific rigor.

Because in the end, evidence-based medicine is only as strong as the integrity of the evidence itself.